Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

Restricted access

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.

Individual Disclosures for the NCCN Acute Myeloid Leukemia Panel

TU1
  • 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34.

  • 2.

    National Cancer Institute. SEER cancer statistics review, 1975-2015: overview, median age at diagnosis. 2018. Available at: https://seer.cancer.gov/csr/1975_2015/. Accessed March 1, 2019.

  • 3.

    Juliusson G. Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry. Clin Lymphoma Myeloma Leuk 2011;11(Suppl 1):S54–S59.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Leone G, Pagano L, Ben-Yehuda D, . Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007;92:1389–1398.

  • 5.

    Pagana L, Pulsoni A, Tosti ME, .Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia. Br J Haematol 2001;112:109–117.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Pulsoni A, Pagano L, Lo Coco F, . Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood 2002;100:1972–1976.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Kayser S, Döhner K, Krauter J, .German-Austrian AMLSG. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011;117:2137–2145.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Larson RA. Etiology and management of therapy-related myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2007;2007:453–459.

  • 9.

    Hosing C, Munsell M, Yazji S, . Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin’s lymphoma. Ann Oncol 2002;13:450–459.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Lenz G, Dreyling M, Schiegnitz E, . Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004;22:4926–4933.

    • Search Google Scholar
    • Export Citation
  • 11.

    Ferrara F, Mirto S. Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly. Br J Haematol 1996;92:627–631.

  • 12.

    Yamauchi T, Negoro E, Lee S, . A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res 2013;33:3947–3951.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Ley TJ, Miller C, Ding L, .Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368:2059–2074.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Döhner H, Estey E, Grimwade D, . Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129:424–447.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Papaemmanuil E, Gerstung M, Bullinger L, . Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016;374:2209–2221.

  • 16.

    Schuurhuis GJ, Heuser M, Freeman S, . Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018;131:1275–1291.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Fernandez HF, Sun Z, Yao X, . Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249–1259.

  • 18.

    Luskin MR, Lee JW, Fernandez HF, . Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood 2016;127:1551–1558.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Pautas C, Merabet F, Thomas X, . Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 2010;28:808–814.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Teuffel O, Leibundgut K, Lehrnbecher T, . Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol 2013;161:192–203.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Burnett AK, Russell NH, Hills RK, .UK NCRI AML Study Group. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 2015;125:3878–3885.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2015;373:1136–1152.

  • 23.

    Sievers EL, Larson RA, Stadtmauer EA, .Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001;19:3244–3254.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Petersdorf S, Kopecky K, Stuart RK, . Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 2009;114:326–327.

    • Search Google Scholar
    • Export Citation
  • 25.

    Petersdorf SH, Kopecky KJ, Slovak M, . A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013;121:4854–4860.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Burnett AK, Hills RK, Milligan D, . Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011;29:369–377.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Hills RK, Castaigne S, Appelbaum FR, . Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 2014;15:986–996.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Boissel N, Renneville A, Leguay T, . Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. Haematologica 2015;100:780–785.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Paschka P, Schlenk RF, Weber D, . Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. Leukemia 2018;32:1621–1630.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Fischer T, Stone RM, Deangelo DJ, . Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010;28:4339–4345.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Stone RM, Fischer T, Paquette R, . Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia 2012;26:2061–2068.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Stone RM, Mandrekar SJ, Sanford BL, . Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017;377:454–464.

  • 33.

    Burnett AK, Russell NH, Hills RK. United Kingdom National Cancer Research Institute Acute Myeloid Leukemia Study Group. Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia. Blood 2016;128:449–452.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Lee JH, Joo YD, Kim H, .Cooperative Study Group A for Hematology. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 2011;118:3832–3841.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Lee JH, Kim H, Joo YD, .Cooperative Study Group A for Hematology. Prospective randomized comparison of idarubicin and high-dose daunorubicin in induction chemotherapy for newly diagnosed acute myeloid leukemia. J Clin Oncol 2017;35:2754–2763.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Granfeldt Østgård LS, Medeiros BC, Sengeløv H, . Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol 2015;33:3641–3649.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 37.

    Grimwade D, Hills RK, Moorman AV, .National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354–365.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Cortes JE, Goldberg SL, Feldman EJ, . Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer 2015;121:234–242.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Lancet JE, Cortes JE, Hogge DE, . Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood 2014;123:3239–3246.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Lancet JE, Uy GL, Cortes JE, . CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 2018;36:2684–2692.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Holowiecki J, Grosicki S, Giebel S, . Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol 2012;30:2441–2448.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Willemze R, Suciu S, Meloni G, . High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol 2014;32:219–228.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Bishop JF, Matthews JP, Young GA, . A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;87:1710–1717.

  • 44.

    Bishop JF, Matthews JP, Young GA, . Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Leuk Lymphoma 1998;28:315–327.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 45.

    Weick JK, Kopecky KJ, Appelbaum FR, . A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996;88:2841–2851.

    • Search Google Scholar
    • Export Citation
  • 46.

    Mayer RJ, Davis RB, Schiffer CA, .Cancer and Leukemia Group B. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994;331:896–903.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Li W, Gong X, Sun M, . High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis. PLoS One 2014;9:e110153.

  • 48.

    Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer 2006;107:116–124.

  • 49.

    Bloomfield CD, Lawrence D, Byrd JC, . Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:4173–4179.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Burnett AK, Russell NH, Hills RK, . Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 2013;31:3360–3368.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Löwenberg B, Pabst T, Maertens J, .Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK). Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood 2017;129:1636–1645.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Al-Ali HK, Brand R, van Biezen A, . A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 2007;21:1945–1951.

    • Search Google Scholar
    • Export Citation
  • 53.

    Smith M, Barnett M, Bassan R, . Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 2004;50:197–222.

  • 54.

    Cairoli R, Beghini A, Grillo G, . Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006;107:3463–3468.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Paschka P, Marcucci G, Ruppert AS, .Cancer and Leukemia Group B. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006;24:3904–3911.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 56.

    Park SH, Chi HS, Min SK, . Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk Res 2011;35:1376–1383.

  • 57.

    Chen W, Xie H, Wang H, . Prognostic significance of KIT mutations in core-binding factor acute myeloid leukemia: a systematic review and meta-analysis. PLoS One 2016;11:e0146614.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Jaramillo S, Benner A, Krauter J, . Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. Blood Cancer J 2017;7:e564.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Löwenberg B, Pabst T, Vellenga E, .Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011;364:1027–1036.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Suciu S, Mandelli F, de Witte T, .EORTC and GIMEMA Leukemia Groups. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003;102:1232–1240.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Slovak ML, Kopecky KJ, Cassileth PA, . Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075–4083.

    • Search Google Scholar
    • Export Citation
  • 62.

    Burnett AK, Wheatley K, Goldstone AH, .Medical Research Council Adult and Paediatric Working Parties. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002;118:385–400.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Döhner K, Schlenk RF, Habdank M, . Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005;106:3740–3746.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Schnittger S, Kohl TM, Haferlach T, . KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006;107:1791–1799.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Röllig C, Bornhäuser M, Thiede C, . Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol 2011;29:2758–2765.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Aldoss I, Pullarkat V. Therapy-related acute myeloid leukemia with favorable cytogenetics: still favorable? Leuk Res 2012;36:1547–1551.

  • 67.

    Farag SS, Ruppert AS, Mrózek K, . Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol 2005;23:482–493.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 68.

    Stone RM, Mandrekar S, Sanford BL, . The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myEloid leukemia (AML) patients (pts) Age 18–60 with FLT3 mutations (muts) [abstract]. Blood 2015;126:6.

    • Search Google Scholar
    • Export Citation
  • 69.

    Appelbaum FR, Gundacker H, Head DR, . Age and acute myeloid leukemia. Blood 2006;107:3481–3485.

  • 70.

    Kantarjian H, O’brien S, Cortes J, . Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106:1090–1098.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Klepin HD, Geiger AM, Tooze JA, . Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood 2013;121:4287–4294.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Sherman AE, Motyckova G, Fega KR, . Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res 2013;37:998–1003.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Krug U, Röllig C, Koschmieder A, .Study Alliance Leukemia Investigators. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 2010;376:2000–2008.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Walter RB, Othus M, Borthakur G, . Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011;29:4417–4424.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Sorror ML, Storer BE, Fathi AT, . Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality. JAMA Oncol 2017;3:1675–1682.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Gardin C, Turlure P, Fagot T, . Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007;109:5129–5135.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Gardin C, Chevret S, Pautas C, . Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. J Clin Oncol 2013;31:321–327.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Löwenberg B, Ossenkoppele GJ, van Putten W, .Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361:1235–1248. [Correction available at https://www.nejm.org/doi/full/10.1056/NEJMx100006.]

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Burnett AK, Russell NH, Hunter AE, .UK National Cancer Research Institute AML Working Group. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 2013;122:1384–1394.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Faderl S, Ravandi F, Huang X, . A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638–1645.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Foran JM, Sun Z, Claxton DF, . Importance of achieving complete remission (CR) after intensive therapy for acute myeloid leukemia (AML) in older adults age ≥60 years: analysis of risk factors for early mortality and re-induction, and impact of quality of response on overall survival (OS) in the ECOG-ACRIN E2906 randomized trial [abstract]. Blood 2016;128:339.

    • Search Google Scholar
    • Export Citation
  • 82.

    Kantarjian HM, Erba HP, Claxton D, . Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010;28:549–555.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Martínez-Cuadrón D, Montesinos P, Oriol A, . Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia. Ann Hematol 2014;93:43–46.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    Amadori S, Suciu S, Stasi R, . Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). J Clin Oncol 2013;31:4424–4430.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Burnett AK, Russell NH, Hills RK, . Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012;30:3924–3931.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Castaigne S, Pautas C, Terré C, .Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012;379:1508–1516.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Loke J, Khan JN, Wilson JS, . Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. Ann Hematol 2015;94:361–373.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88.

    Kharfan-Dabaja MA, Hamadani M, Reljic T, . Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol 2013;163:315–325.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 89.

    Li X, Xu SN, Qin DB, . Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials. Ann Oncol 2014;25:455–461.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Schlenk RF, Weber D, Fiedler W, .German-Austrian AML Study Group. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood 2019;133:840–851.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Fenaux P, Mufti GJ, Hellstrom-Lindberg E, .International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223–232.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Fenaux P, Mufti GJ, Hellström-Lindberg E, . Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562–569.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Dombret H, Seymour JF, Butrym A, . International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 2015;126:291–299.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Cashen AF, Schiller GJ, O’Donnell MR, . Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010;28:556–561.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Issa JP, Garcia-Manero G, Giles FJ, . Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635–1640.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96.

    Blum W, Garzon R, Klisovic RB, . Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010;107:7473–7478.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 97.

    Welch JS, Petti AA, Miller CA, . TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med 2016;375:2023–2036.

  • 98.

    Short NJ, Kantarjian HM, Loghavi S, . Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 2019;6:e29–e37.

    • Search Google Scholar
    • Export Citation
  • 99.

    Kantarjian HM, Thomas XG, Dmoszynska A, . Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012;30:2670–2677.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    DiNardo CD, Pratz KW, Letai A, . Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 2018;19:216–228.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    DiNardo CD, Pratz K, Pullarkat V, . Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 2019;133:7–17.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 102.

    Wei AH, Strickland SA, Jr., Hou JZ, . Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study [published online March 20, 2019]. J Clin Oncol. doi: 10.1200/JCO.18.01600.

    • Search Google Scholar
    • Export Citation
  • 103.

    Burnett AK, Milligan D, Prentice AG, . A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007;109:1114–1124.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Faderl S, Ravandi F, Huang X, . Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 2012;118:4471–4477.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Cortes JE, Heidel FH, Hellmann A, . Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia 2019;33:379–389.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Amadori S, Suciu S, Selleslag D, . Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol 2016;34:972–979.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107.

    Jurcic JG. Androgen maintenance therapy for acute myeloid leukemia. J Clin Oncol 2017;35:381–383.

  • 108.

    Pigneux A, Béné MC, Guardiola P, . Addition of androgens improves survival in elderly patients with acute myeloid leukemia: a GOELAMS study. J Clin Oncol 2017;35:387–393.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Roboz GJ, DiNardo CD, Stein EM, . Ivosidenib (AG-120) induced durable remissions and transfusion independence in patients with IDH1-mutant untreated AML: results from a phase 1 dose escalation and expansion study [abstract]. Blood 2018;132:561.

    • Search Google Scholar
    • Export Citation
  • 110.

    Stein EM, Shoben A, Borate U, . Enasidenib is highly active in previously untreated IDH2 mutant AML: early results from the beat AML master trial [abstract]. Blood 2018;132:287.

    • Search Google Scholar
    • Export Citation
  • 111.

    Stein EM, DiNardo CD, Pollyea DA, . Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 2017;130:722–731.

  • 112.

    DiNardo CD, Stein EM, de Botton S, . Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 2018;378:2386–2398.

  • 113.

    Birendra KC, DiNardo CD. Evidence for clinical differentiation and differentiation syndrome in patients with acute myeloid leukemia and IDH1 mutations treated with the targeted mutant IDH1 inhibitor, AG-120. Clin Lymphoma Myeloma Leuk 2016;16:460–465.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 114.

    Fathi AT, DiNardo CD, Kline I, .AG221-C-001 Study Investigators. Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1/2 study. JAMA Oncol 2018;4:1106–1110.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 115.

    Sanz MA, Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood 2014;123:2777–2782.

  • 116.

    Ravandi F, Alattar ML, Grunwald MR, . Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 2013;121:4655–4662.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 117.

    Esteve J, Schots R, Bernal Del Castillo T, . Multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in newly diagnosed FLT3 Mutated FLT3mut+) acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy: findings from the safety cohort. Blood 2018;132:2736.

    • Search Google Scholar
    • Export Citation
  • 118.

    Perl AE, Altman JK, Cortes J, . Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol 2017;18:1061–1075.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 119.

    Herr AL, Labopin M, Blaise D, .Acute Leukemia Working Party or the European Group for Blood and Marrow Transplantation. HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. Leukemia 2007;21:129–135.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    Storb R. Can reduced-intensity allogeneic transplantation cure older adults with AML? Best Pract Res Clin Haematol 2007;20:85–90.

  • 121.

    Estey E, de Lima M, Tibes R, . Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007;109:1395–1400.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 122.

    Martino R, Valcárcel D, Brunet S, . Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission. Bone Marrow Transplant 2008;41:33–38.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 123.

    Kurosawa S, Yamaguchi T, Uchida N, . Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission. Biol Blood Marrow Transplant 2011;17:401–411.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 124.

    Farag SS, Maharry K, Zhang MJ, .Acute Leukemia Committee of the Center for International Blood and Marrow Transplant Research and Cancer and Leukemia Group B. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 2011;17:1796–1803.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 125.

    Devine SM, Owzar K, Blum W, . Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from cancer and leukemia group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol 2015;33:4167–4175.

    • Search Google Scholar
    • Export Citation
  • 126.

    Versluis J, Hazenberg CL, Passweg JR, .HOVON and SAKK Leukemia Groups. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. Lancet Haematol 2015;2:e427–e436.

    • Crossref
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 9252 9252 1758
PDF Downloads 3678 3678 742
EPUB Downloads 0 0 0